Jasper Therapeutics receives FDA IND clearance for Phase 1b/2a study of briquilimab in chronic spontaneous urticaria

Jasper Therapeutics, Inc.

FDA cleared IND for Phase 1b/2a repeat dose study of subcutaneous briquilimab in CSU patients.
First patient expected by end of 2023; early data from initial cohorts by mid-2024.
Separate CIndU proof-of-concept study to start Q1 2024 with initial data by year-end 2024.
Study enrolls ~40 patients across 6 cohorts; primary endpoints safety/tolerability, secondary efficacy/PK.
Targets CSU patients ineligible for or refractory to omalizumab, a high unmet need population.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.